查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087924

肝腎症候群治療市場：依產品類型、給藥途徑、患者病情嚴重程度、治療方法、藥物類別及最終用戶分類－2026-2032年全球市場預測

Hepatorenal Syndrome Treatment Market by Product Type, Route Of Administration, Patient Severity, Treatment Modality, Drug Class, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝腎症候群治療市場將成長至 84.7 億美元，複合年成長率為 7.45%。

主要市場統計數據
基準年 2025 51.2億美元
預計年份：2026年 54.6億美元
預測年份：2032年 84.7億美元
複合年成長率 (%) 7.45%

肝腎症候群（HRS）的治療已成為進行性肝病治療的首要任務。這是因為HRS-AKI是一種危及生命的腎衰竭，常見於伴隨肝硬化、腹水和嚴重循環障礙的患者。目前的臨床實踐著重於快速診斷、在適當情況下停用腎毒性藥物和利尿劑、補充白蛋白、控制感染、使用血管收縮劑治療以及及時評估是否適合肝臟移植。

該市場受多種因素驅動，包括提高生存率、促進急性腎損傷康復、減少重症監護的使用以及為合格的患者提供肝移植機會。雖然特利加壓素與白蛋白的聯合應用增強了藥物治療的合理性，但去甲腎上腺素或Midodrine與Octreotide的聯合應用仍然是重要的治療選擇，具體取決於監管規定、治療環境和患者的風險狀況。此外，全球酒精性肝病、代謝紊亂相關脂肪肝、病毒性肝炎併發症和補償肝硬化的負擔日益加重，也影響市場需求。

HRS治療格局的變革性變化

在肝病學和重症監護領域，我們正從傳統的延遲救命治療轉向透過採用標準化標準、多學科診療路徑以及肝腎綜合評估來早期識別肝腎症候群相關急性腎損傷（HRS-AKI）。國際腹水俱樂部分類有助於將臨床術語從傳統的“HRS 1型”和“HRS 2型”轉變為“HRS-AKI”和“非AKI”，從而支持設計更一致的診斷和臨床檢測方法。

人工智慧對 HRS 護理的累積影響

人工智慧（AI）並非要取代醫師的判斷，而是透過預測分析、臨床決策支援和營運最佳化，開始影響肝腎症候群（HRS）的治療。利用電子健康記錄訓練的AI模型可以幫助識別急性腎損傷（AKI）、感染疾病、膿毒症、消化道出血或進展為HRS的高風險肝硬化患者，從而能夠透過輸注白蛋白、合理使用抗生素和調整藥物管理方案進行早期療育。

HRS治療市場的關鍵區域洞察

由於北美擁有先進的移植基礎設施、循證肝病診療方案的高採納率，以及特利加壓素在美國獲批後監管政策的明確化，該地區在肝腎症候群的治療方面仍然處於領先地位。儘管該地區受益於專業的肝病中心、重症監護能力和強大的臨床研究網路，但農村地區、未投保者、原住民社區以及酒精性肝病患者在醫療服務獲取方面仍然存在差距。

用於HRS市場策略規劃的關鍵群體洞察

隨著新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國肝病專科診療服務的擴展，東協市場的重要性日益凸顯。需求主要源自於病毒性肝炎後遺症、酒精性肝病以及日益增多的代謝性肝病，但能否獲得先進的肝腎症候群（HRS）治療取決於醫院的排名、保險報銷情況、白蛋白供應以及能否取得肝移植資訊。

各國對肝腎綜合症治療的見解

由於已通過核准的特利加壓素的供應、移植中心診療方案的廣泛應用、豐富的重症監護資源以及活躍的臨床研究，美國是肝腎症候群（HRS）治療最具商業吸引力的市場。在加拿大，省級醫保框架強調商業性專科診療。同時，在墨西哥，儘管肝硬化負擔日益加重，但肝臟移植和高級住院治療的可近性仍存在差異。巴西是拉丁美洲最大的市場，主要城市擁有強大的三級醫療機構，但在肝病學、透析、白蛋白和肝臟移植的可及性方面存在區域差異。

人力資源服務業領導者使用的實用建議

產業領導者應優先考慮基於實證醫學的、具有臨床意義的結局指標，例如肝腎症候群的逆轉、腎移植過渡治療、避免或延緩腎臟替代治療、住院時間、生存率和安全性監測。商業性和臨床策略應反映肝腎症候群的治療決策是由肝病學家、重症監護醫師、腎臟科醫師、移植團隊、藥劑師、護理師和醫院藥局委員會共同製定的。

HRS治療分析調查方法

本執行摘要基於結構化的調查方法，該方法結合了檢驗的二手研究、臨床指南審查、監管分析和市場三角驗證。主要證據來源包括同行評審的肝病學和腎臟病學文獻、美國肝病研究協會 (AASLD) 和歐洲肝病研究協會 (EASL) 指南、國際腹水俱樂部標準、美國製劑資訊、臨床實驗室登記資料、移植機構數據以及世界衛生組織 (WHO)、經濟合作暨發展組織 (OECD) 和各國衛生組織等公共衛生資訊來源的資訊。

結論：肝腎症候群治療的未來

隨著肝腎症候群-急性腎損傷（HRS-AKI）診斷標準化、基於白蛋白的血管收縮劑治療、以移植為中心的護理以及真實世界安全性監測在臨床實踐中日益重要，肝腎症候群治療市場正朝著循證醫學方向發展。特利加壓素的核准和應用使治療方案、患者選擇、呼吸風險管理和治療後監測等問題受到更多關注，同時，其他血管收縮劑治療策略在各個醫療體系中仍然至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：肝腎症候群治療市場：依產品類型分類

  • 品牌
  • 非專利的

第8章：肝腎症候群治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第9章：肝腎症候群治療市場：依患者病情嚴重程度分類

  • 一型
  • II 型

第10章 肝腎症候群治療市場：依治療方法分類

  • 藥物治療
  • 腎臟替代療法
  • 經頸靜脈肝內門體分流術
  • 肝臟移植

第11章：肝腎症候群治療市場：依藥物類別分類

  • 血管加壓素類似物
  • 兒茶酚胺
  • α-腎上腺素促效劑
  • 生長抑制素類似物
  • 血漿置換液

第12章：肝腎症候群治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章 肝腎症候群治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：肝腎症候群治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：肝腎症候群治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Aetna Inc.
  • Baxter International Inc
  • Becton, Dickinson and Company
  • Biocon Limited
  • BioVie Inc
  • Cadila Healthcare Limited
  • Cumberland Pharmaceuticals Inc
  • Edwards Lifesciences Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Mallinckrodt Inc
  • Medtronic plc
  • Neovii Pharmaceuticals AG
  • Novartis International AG
  • Orphan Therapeutics, LLC
  • PharmaIN Corporation
  • Samarth Life Sciences Pvt Ltd.
  • Swastik Life Sciences
  • United BIoTech Pvt Ltd.
Product Code: MRR-035DA3C63700

The Hepatorenal Syndrome Treatment Market is projected to grow by USD 8.47 billion at a CAGR of 7.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.12 billion
Estimated Year [2026] USD 5.46 billion
Forecast Year [2032] USD 8.47 billion
CAGR (%) 7.45%

Hepatorenal syndrome treatment is becoming a high-priority focus within advanced liver disease care because HRS-AKI is a life-threatening form of functional kidney failure that occurs in patients with cirrhosis, ascites, and severe circulatory dysfunction. Current clinical practice centers on rapid diagnosis, withdrawal of nephrotoxic agents and diuretics when appropriate, albumin-supported volume expansion, infection control, vasoconstrictor therapy, and timely liver transplant evaluation.

The market is shaped by the need to improve survival, reverse acute kidney injury, reduce intensive care utilization, and bridge eligible patients to liver transplantation. Terlipressin plus albumin has strengthened the evidence base for pharmacologic management, while norepinephrine and midodrine with octreotide remain important alternatives depending on regulatory availability, care setting, and patient risk profile. Demand is also influenced by the growing burden of alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, viral hepatitis complications, and decompensated cirrhosis worldwide.

Transformative Shifts in the HRS Treatment Landscape

The hepatology and critical care landscape is shifting from delayed rescue treatment toward earlier recognition of HRS-AKI using standardized criteria, multidisciplinary care pathways, and integrated liver-kidney assessment. The International Club of Ascites classification has helped move clinical terminology away from older type 1 and type 2 HRS language toward HRS-AKI and non-AKI phenotypes, supporting more consistent diagnosis and trial design.

Therapeutic change is being driven by wider clinical use of vasoconstrictor therapy with albumin, the U.S. Food and Drug Administration approval of terlipressin for adults with HRS involving rapid reduction in kidney function, and increasing awareness of respiratory failure risk requiring careful patient selection and oxygenation monitoring. Hospitals are also reassessing where treatment should occur, as norepinephrine often requires intensive monitoring while terlipressin may enable protocolized use in specialized liver units when safety criteria are met.

Another major shift is the emphasis on transplant-centered decision-making. Because liver transplantation remains the definitive treatment for many eligible patients with HRS, payers, transplant centers, and hospital networks are aligning HRS protocols with early referral, MELD-based risk stratification, renal replacement therapy planning, and post-transplant kidney outcome monitoring.

Cumulative Impact of Artificial Intelligence on HRS Care

Artificial intelligence is beginning to influence hepatorenal syndrome treatment through predictive analytics, clinical decision support, and operational optimization rather than replacing physician judgment. AI models trained on electronic health records can help identify patients with cirrhosis who are at elevated risk for AKI, infection, sepsis, gastrointestinal bleeding, or progression toward HRS, enabling earlier intervention with albumin, antimicrobial stewardship, and medication review.

In research and clinical development, AI can improve cohort identification for HRS trials, detect eligibility criteria more efficiently, and support real-world evidence generation across transplant centers and tertiary hospitals. Natural language processing can extract ascites status, creatinine trends, vasoconstrictor exposure, albumin use, renal replacement therapy, and transplant outcomes from unstructured clinical notes, creating more reliable longitudinal datasets.

The cumulative impact of AI will depend on rigorous validation, explainability, bias monitoring, and compliance with health data privacy requirements. HRS patients are medically complex and often underrepresented in datasets, so AI tools must be evaluated against clinical outcomes such as verified HRS reversal, need for renal replacement therapy, respiratory complications, waitlist mortality, and transplant-free survival.

Key Regional Insights Across HRS Treatment Markets

North America remains a leading region for hepatorenal syndrome treatment because of advanced transplant infrastructure, high adoption of evidence-based hepatology protocols, and regulatory clarity following the United States approval of terlipressin. The region benefits from specialized liver centers, intensive care capacity, and strong clinical research networks, although access differences persist across rural communities, uninsured populations, Indigenous communities, and patients with alcohol-associated liver disease.

Europe has a mature treatment environment supported by established hepatology societies, public reimbursement systems, and long-standing clinical experience with terlipressin in several markets. European practice is strongly influenced by EASL guidance, transplant prioritization systems, and hospital-based management of decompensated cirrhosis. The European Union adds scale for harmonized regulatory oversight and pharmacovigilance, while the United Kingdom, Germany, France, Italy, and Spain remain important demand centers for protocolized HRS-AKI care.

Asia-Pacific is expanding as cirrhosis care improves across Japan, China, India, South Korea, Australia, and ASEAN markets. Regional momentum is supported by large patient populations, rising metabolic dysfunction-associated steatotic liver disease, persistent viral hepatitis sequelae, and investment in tertiary hospitals, but constrained by variable transplant access, uneven specialist density, and affordability barriers. Latin America, led by Brazil and Mexico, shows growing need due to decompensated cirrhosis prevalence and improving specialty care, while reimbursement, albumin access, dialysis capacity, and transplant availability remain uneven.

The Middle East is gaining momentum through GCC investments in tertiary care, transplant programs, digital health infrastructure, and hospital modernization, particularly in high-income Gulf states. Africa has substantial unmet need, with care often limited by late presentation, constrained access to albumin, vasoconstrictors, dialysis, and transplant services, and high competing burdens from viral hepatitis, alcohol-related disease, schistosomiasis in selected settings, and infection-associated decompensation.

Key Group Insights for Strategic HRS Market Planning

ASEAN markets are becoming more relevant as specialist hepatology services expand in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Demand is linked to viral hepatitis sequelae, alcohol-related liver disease, and increasing metabolic liver disease, while adoption of advanced HRS treatment depends on hospital tier, reimbursement, albumin availability, and access to transplant referral pathways.

The GCC represents a high-investment healthcare cluster where tertiary hospitals, digital health infrastructure, and transplant capabilities are advancing. Greater protocol standardization across Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman can improve early HRS recognition, albumin stewardship, safe vasoconstrictor use, critical care coordination, and continuity between local hospitals and transplant centers.

The European Union provides a structured environment for regulatory oversight, pharmacovigilance, and guideline-driven cirrhosis care, supporting consistent clinical pathways across member states despite national reimbursement variation. BRICS countries represent a large-volume opportunity, with China, India, Brazil, Russia, and South Africa collectively carrying significant liver disease burden and requiring scalable, cost-conscious HRS care models that can operate across tertiary hospitals and resource-constrained public systems.

G7 markets are characterized by strong research capacity, advanced hospital systems, transplant expertise, and higher adoption of novel therapeutics, making them influential in clinical evidence generation and post-approval safety monitoring. NATO countries overlap substantially with North American and European advanced care systems, where military and civilian medical networks may support critical care readiness, supply continuity, cross-border research collaboration, and resilient access to essential therapies during system disruptions.

Key Country Insights in Hepatorenal Syndrome Treatment

The United States is the most commercially visible HRS treatment market due to approved terlipressin availability, high use of transplant-center protocols, intensive care resources, and substantial clinical research activity. Canada emphasizes evidence-based specialty care within provincial reimbursement frameworks, while Mexico faces a growing cirrhosis burden and uneven access to transplant and advanced inpatient therapies. Brazil is the largest Latin American market, with strong tertiary hospitals in major urban centers but regional disparities in hepatology, dialysis, albumin, and transplant access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are important HRS treatment markets because of established hepatology expertise, public health systems, and transplant networks. Germany and France offer advanced hospital infrastructure and clinical research depth, while Italy and Spain have significant cirrhosis care experience and transplant activity. The United Kingdom's liver services support guideline-driven care and transplant referral pathways, although hospital capacity pressures can affect complex inpatient management. Russia has sizable unmet need, with adoption shaped by hospital capacity, procurement, specialist availability, and regional differences in access to advanced liver care.

China and India represent high-volume Asia-Pacific opportunities as large populations, expanding hospital infrastructure, persistent viral hepatitis sequelae, alcohol-related liver disease, and rising metabolic liver disease increase demand for decompensated cirrhosis management. Japan and South Korea have sophisticated specialty care systems, strong diagnostics, and advanced hospital capabilities, supporting protocolized HRS management and careful safety monitoring. Australia combines high-quality hepatology care with transplant expertise, though geographic dispersion can affect timely access for remote and Indigenous populations.

Actionable Recommendations for HRS Industry Leaders

Industry leaders should prioritize evidence-based positioning around clinically meaningful outcomes, including HRS reversal, transplant bridging, avoidance or delay of renal replacement therapy, hospital length of stay, survival, and safety monitoring. Commercial and clinical strategies should reflect that HRS treatment decisions are made by hepatologists, intensivists, nephrologists, transplant teams, pharmacists, nurses, and hospital formulary committees.

Manufacturers and healthcare organizations should invest in education that improves early diagnosis, appropriate albumin use, vasoconstrictor selection, respiratory risk assessment, renal replacement therapy planning, and escalation to transplant evaluation. Real-world evidence programs can strengthen confidence by tracking patient selection, dosing patterns, treatment response, adverse events, oxygenation status, recurrence, and outcomes across diverse hospital settings.

Market access strategies should be region-specific. In advanced markets, the emphasis should be on value demonstration, formulary pathway integration, and pharmacovigilance, while emerging markets require affordability solutions, supply reliability, specialist training, and partnerships with liver centers. Digital tools, including validated AI-based risk alerts, should be implemented cautiously with clinician oversight, transparent governance, and measurable quality-improvement endpoints.

Research Methodology for the HRS Treatment Analysis

This executive summary is based on a structured research methodology combining verified secondary research, clinical guideline review, regulatory analysis, and market triangulation. Core evidence sources include peer-reviewed hepatology and nephrology literature, AASLD and EASL guidance, International Club of Ascites criteria, United States prescribing information, clinical trial registries, transplant organization data, and public health sources such as WHO, OECD, and national health agencies.

The analysis evaluates treatment pathways, regulatory availability, clinical adoption drivers, reimbursement dynamics, regional healthcare capacity, and country-level differences in transplant access. Insights are validated by comparing multiple independent sources and prioritizing data tied to clinical outcomes, regulatory decisions, guideline recommendations, and published evidence rather than speculative market claims.

Where quantitative market estimates are not publicly verifiable, the summary avoids unsupported figures and focuses on evidence-backed directional trends. This approach supports relevance while maintaining the level of accuracy expected by healthcare stakeholders, investors, manufacturers, providers, and policy decision-makers.

Conclusion: The Future of Hepatorenal Syndrome Treatment

The hepatorenal syndrome treatment market is entering a more evidence-driven phase as standardized HRS-AKI diagnosis, vasoconstrictor therapy with albumin, transplant-centered care, and real-world safety monitoring become central to clinical practice. The approval and adoption of terlipressin have increased focus on treatment protocols, patient selection, respiratory risk management, and post-treatment monitoring, while alternative vasoconstrictor strategies remain important across varied health systems.

Future progress will depend on earlier recognition of decompensated cirrhosis, broader access to specialist care, stronger transplant referral pathways, resilient albumin and vasoconstrictor supply, and regionally appropriate reimbursement models. Organizations that combine clinical rigor, market access discipline, pharmacovigilance, and responsible digital innovation will be best positioned to improve outcomes for patients with HRS while building sustainable leadership in advanced liver disease care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatorenal Syndrome Treatment Market, by Product Type

  • 7.1. Branded
  • 7.2. Generic

8. Hepatorenal Syndrome Treatment Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral

9. Hepatorenal Syndrome Treatment Market, by Patient Severity

  • 9.1. Type I
  • 9.2. Type II

10. Hepatorenal Syndrome Treatment Market, by Treatment Modality

  • 10.1. Pharmacotherapy
  • 10.2. Renal Replacement Therapy
  • 10.3. Transjugular Intrahepatic Portosystemic Shunt
  • 10.4. Liver Transplantation

11. Hepatorenal Syndrome Treatment Market, by Drug Class

  • 11.1. Vasopressin Analogs
  • 11.2. Catecholamines
  • 11.3. Alpha-Adrenergic Agonists
  • 11.4. Somatostatin Analogs
  • 11.5. Plasma Expanders

12. Hepatorenal Syndrome Treatment Market, by End User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Hepatorenal Syndrome Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Hepatorenal Syndrome Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hepatorenal Syndrome Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Aetna Inc.
  • 17.2. Baxter International Inc
  • 17.3. Becton, Dickinson and Company
  • 17.4. Biocon Limited
  • 17.5. BioVie Inc
  • 17.6. Cadila Healthcare Limited
  • 17.7. Cumberland Pharmaceuticals Inc
  • 17.8. Edwards Lifesciences Corporation
  • 17.9. F. Hoffmann-La Roche AG
  • 17.10. GlaxoSmithKline plc
  • 17.11. Mallinckrodt Inc
  • 17.12. Medtronic plc
  • 17.13. Neovii Pharmaceuticals AG
  • 17.14. Novartis International AG
  • 17.15. Orphan Therapeutics, LLC
  • 17.16. PharmaIN Corporation
  • 17.17. Samarth Life Sciences Pvt Ltd.
  • 17.18. Swastik Life Sciences
  • 17.19. United Biotech Pvt Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYPE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYPE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYPE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RENAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RENAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CATECHOLAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATECHOLAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CATECHOLAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA EXPANDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA EXPANDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA EXPANDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 138. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)